Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1151 - 1200 of 1864 results
- Plasma Interleukin-6 and Fatigue in Terminally Ill Cancer Patients.
- Temporal treatment with interferon-beta prevents hepatocellular carcinoma in hepatitis B virus X gene transgenic mice.
- Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
- Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.
- Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.
- Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
- Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
- Inhibition of human ovarian tumor growth by cytokine-induced killer cells.
- Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
- TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
- A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
- Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells.
- Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.
- Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
- Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer.
- Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
- In vivo bioluminescence visualization of antitumor effects by human MUC1 vaccination.
- Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer (January).
- Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
- ErbB-2 Receptor Cooperates with E6/E7 Oncoproteins of HPV Type 16 in Breast Tumorigenesis.
- Enhanced Immunity to Intracerebral Breast Cancer in Mice Immunized With a cDNA-based Vaccine Enriched for Immunotherapeutic Cells.
- Interferon-alpha in Combination With Chemotherapy has Potent Antiangiogenic Properties in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma.
- Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas.
- Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma.
- Development of a Potency Assay for Human Dendritic Cells: IL-12p70 Production.
- Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients.
- New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
- Oncolytic Virotherapy for Prostate Cancer by E1A, E1B Mutant Adenovirus.
- Vaccination with Allogeneic GM-CSF Gene-Modified Lung Cancer Cells: Antitumor Activity Comparing with that Induced by Autologous Vaccine.
- Preparation and Characterization of New Anti-PSMA Monoclonal Antibodies with Potential Clinical Use.
- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
- Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
- Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
- Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium.
- An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer.
- Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with Carboplatin and Paclitaxel: analysis of eastern cooperative oncology group trial 4599.
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia.
- The Immunogenicity of the hTERT540-548 Peptide in Cancer.
- Phase I immunotherapeutic trial with long peptides spanning the e6 and e7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
- Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine.
- Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
- Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
- Novel inhibitors for murine and human leukemia inhibitory factor based on fused soluble receptors.
- VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment.
- A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma.
- Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
- Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
- Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.
- TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines.